Eritel CH 40 Tablet is a combination antihypertensive medication containing Telmisartan 40 mg and Chlorthalidone 12.5 mg. Telmisartan is an angiotensin II receptor antagonist that selectively blocks the binding of angiotensin II to the AT1 receptor, thereby inhibiting vasoconstriction and aldosterone secretion, which results in vasodilation and reduced blood pressure. Chlorthalidone is a thiazide-like diuretic that promotes the excretion of sodium and water by inhibiting sodium reabsorption in the distal convoluted tubules of the kidneys, leading to decreased plasma volume and peripheral vascular resistance. The synergistic action of these two agents provides effective management of hypertension, reducing the risk of cardiovascular events such as stroke, myocardial infarction, and heart failure. Eritel CH 40 Tablet is indicated for the treatment of essential hypertension in patients who require combination therapy to achieve adequate blood pressure control. It is contraindicated in patients with hypersensitivity to any component, anuria, or severe renal impairment. Caution is advised in patients with electrolyte imbalances, hepatic dysfunction, or gout. Regular monitoring of blood pressure, renal function, and electrolytes is recommended during therapy. Eritel CH 40 Tablet should be used under medical supervision with adherence to prescribed dosage and lifestyle modifications for optimal therapeutic outcomes.